Bone Biologics Total Assets 2020-2025 | BBLG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Bone Biologics total assets from 2020 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Bone Biologics total assets from 2020 to 2025. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.1B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$135.7B
Vertex Pharmaceuticals (VRTX)	$119.2B
Bristol Myers Squibb (BMY)	$94.5B
CSL (CSLLY)	$78.8B
GSK (GSK)	$77.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$40.6B
Argenex SE (ARGX)	$34B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$20.5B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.2B
Moderna (MRNA)	$12.2B
Exelixis (EXEL)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
Ascendis Pharma (ASND)	$10.7B
QIAGEN (QGEN)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.3B